Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and business updates. The company achieved 50% enrollment in Phase 1b trial of ATR-12 for Netherton syndrome, showing promising safety data in the first five patients. Additionally, Azitra secured a $20 million equity line of credit from Alumni Capital LP.
The company's pipeline includes ATR-04, targeting EGFRi-associated rash affecting approximately 150,000 US patients annually. Key upcoming milestones include first patient dosing in ATR-04's Phase 1/2 trial in Q3 2025 and ATR-12's Phase 1b topline data in Q1 2026. Financial results show R&D expenses of $1.4 million, G&A expenses of $1.5 million, and a net loss of $2.9 million, with cash position at $1.0 million.
Azitra (NYSE American: AZTR), azienda biofarmaceutica in fase clinica, ha reso noti i risultati finanziari del Q2 2025 e aggiornamenti aziendali. La società ha raggiunto il 50% di arruolamento nello studio di Fase 1b di ATR-12 per la sindrome di Netherton, mostrando dati di sicurezza promettenti nei primi cinque pazienti. Inoltre, Azitra ha ottenuto una linea di credito azionaria da $20 million da Alumni Capital LP.
La pipeline include ATR-04, che mira all'eruzione cutanea associata agli inibitori di EGFR e interessa circa 150,000 pazienti negli USA ogni anno. Tra i prossimi traguardi figurano la prima somministrazione al paziente nello studio di Fase 1/2 di ATR-04 nel Q3 2025 e i dati topline della Fase 1b di ATR-12 nel Q1 2026. I risultati finanziari mostrano costi di R&S per $1.4 million, spese G&A per $1.5 million e una perdita netta di $2.9 million, con una posizione di cassa di $1.0 million.
Azitra (NYSE American: AZTR), compañía biofarmacéutica en fase clínica, informó resultados financieros del 2T 2025 y novedades corporativas. La empresa logró el 50% de inscripción en el ensayo de Fase 1b de ATR-12 para el síndrome de Netherton, mostrando datos de seguridad prometedores en los primeros cinco pacientes. Además, Azitra aseguró una línea de crédito accionaria de $20 million con Alumni Capital LP.
La cartera incluye ATR-04, orientada a la erupción asociada a inhibidores de EGFR, que afecta aproximadamente a 150,000 pacientes en EE. UU. cada año. Próximos hitos: dosificación del primer paciente en el ensayo de Fase 1/2 de ATR-04 en el 3T 2025 y datos topline de la Fase 1b de ATR-12 en el 1T 2026. Las finanzas muestran gastos de I+D por $1.4 million, gastos G&A por $1.5 million y una pérdida neta de $2.9 million, con efectivo disponible de $1.0 million.
Azitra (NYSE American: AZTR)는 임상 단계의 바이오제약 기업으로 2025년 2분기 재무 실적 및 사업 업데이트를 보고했습니다. 회사는 Netherton 증후군 대상 ATR-12의 Phase 1b 임상에서 50% 등록을 달성했으며, 처음 다섯 환자에서 유망한 안전성 데이터를 확인했습니다. 또한 Azitra는 Alumni Capital LP로부터 $20 million 규모의 주식 신용 한도를 확보했습니다.
파이프라인에는 EGFR 억제제 관련 발진을 표적으로 하는 ATR-04가 포함되어 있으며, 이는 미국에서 연간 약 150,000명의 환자에게 영향을 미칩니다. 향후 주요 마일스톤으로는 ATR-04의 Phase 1/2 시험에서 2025년 3분기 첫 환자 투약과 ATR-12의 Phase 1b 톱라인 데이터가 2026년 1분기에 발표되는 것이 있습니다. 재무 실적은 R&D 비용 $1.4 million, G&A 비용 $1.5 million, 순손실 $2.9 million, 현금 잔액 $1.0 million을 기록했습니다.
Azitra (NYSE American: AZTR), société biopharmaceutique en phase clinique, a publié ses résultats financiers du T2 2025 et des mises à jour opérationnelles. La société a atteint 50% d'enrôlement dans l'essai de phase 1b d'ATR‑12 pour le syndrome de Netherton, affichant des données de sécurité prometteuses chez les cinq premiers patients. En outre, Azitra a obtenu une ligne de crédit en actions de $20 million auprès d'Alumni Capital LP.
Le portefeuille comprend ATR‑04, visant l'éruption cutanée associée aux inhibiteurs d'EGFR, qui toucherait environ 150,000 patients aux États‑Unis chaque année. Les jalons à venir incluent l'administration au premier patient de l'essai de phase 1/2 d'ATR‑04 au T3 2025 et les données topline de la phase 1b d'ATR‑12 au T1 2026. Les résultats financiers indiquent des dépenses R&D de $1.4 million, des dépenses G&A de $1.5 million et une perte nette de $2.9 million, avec une trésorerie de $1.0 million.
Azitra (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in der klinischen Phase, berichtete über die Finanzergebnisse und Unternehmensupdates für Q2 2025. Das Unternehmen erreichte 50% Einschreibung in der Phase‑1b‑Studie von ATR‑12 für das Netherton‑Syndrom und zeigte vielversprechende Sicherheitsdaten bei den ersten fünf Patienten. Zusätzlich sicherte sich Azitra eine $20 million Eigenkapitallinie von Alumni Capital LP.
Die Pipeline umfasst ATR‑04, das auf EGFRi‑assoziierten Hautausschlag abzielt und jährlich rund 150,000 US‑Patienten betrifft. Wichtige anstehende Meilensteine sind die Erstpatientendosierung in der Phase‑1/2‑Studie von ATR‑04 im Q3 2025 und die Topline‑Daten der Phase‑1b‑Studie von ATR‑12 im Q1 2026. Die Finanzergebnisse zeigen F&E‑Aufwendungen von $1.4 million, G&A‑Aufwendungen von $1.5 million und einen Nettoverlust von $2.9 million, bei einer Barposition von $1.0 million.
- Secured $20 million equity line of credit for clinical pipeline funding
- Achieved 50% enrollment in Phase 1b trial of ATR-12 with promising safety profile
- Targeting large market opportunity with ATR-04 (150,000 US patients annually)
- Clear pipeline milestones set for Q3 2025 and Q1 2026
- Increased net loss to $2.9 million from $2.6 million year-over-year
- Low cash position of $1.0 million as of June 30, 2025
- Higher R&D expenses at $1.4 million compared to $1.1 million in previous year
Insights
Azitra reports promising safety data for Netherton syndrome treatment while facing significant cash constraints with $1M remaining.
Azitra's Q2 2025 results show both clinical progress and financial challenges. The company has reached 50% enrollment in its Phase 1b trial for ATR-12 in Netherton syndrome with promising initial safety results. This represents significant advancement for a disease with no approved treatments, potentially offering hope for patients with this rare chronic condition.
The company is also advancing its ATR-04 program for EGFR inhibitor-associated rash, which affects approximately 150,000 patients annually in the US. First patient dosing is expected in Q3 2025, with the trial design recently presented at ASCO.
However, Azitra's financial position is concerning. With just
The recently established equity line of credit with Alumni Capital LP (up to
Q2 2025 and Recent Business Highlights
- Announced initial safety results and
50% enrollment of the Phase 1b clinical trial of the ATR-12 program in Netherton syndrome, demonstrating a promising safety profile
- Announced acceptance of poster detailing the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- Entered into a purchase agreement for up to
$20 million
"The first half of 2025 was a vital period for Azitra as we hit a key milestone in our first-in-class, precision, live biotherapeutic candidates designed for major undertreated dermatological diseases," said Francisco Salva, CEO of Azitra. "For ATR-12, our lead program targeting the rare, chronic and devastating Netherton syndrome, we announced promising safety data in the first five patients dosed with ATR12-351, and we believe this novel approach has potential to be life-changing for these patients. Netherton syndrome has a high unmet need with no approved treatment options."
Mr. Salva continued: "We also announced the design of our Phase 1/2 trial with our ATR-04 program at ASCO, which is investigating a live biotherapeutic product candidate containing an isolated, naturally derived S. epidermidis strain being developed for the treatment of EGFRi-associated rash. EGFRi-associated rash is a dermatologic toxicity that often accompanies EGFRi treatments for cancer, impacting approximately 150,000 patients in
Mr. Salva concluded: "The remainder of 2025 is anticipated to be a milestone-rich period for Azitra during which we look forward to showcasing the potential of ATR-12 and ATR-04, as well as our unique, proprietary platform for delivering engineered proteins using topical live biotherapeutic products."
Pipeline and Anticipated Milestones
- Q3 2025: First patient to be dosed with for EGFRi-associated rash in a Phase 1/2 trial for ATR-04
- Q1 2026: Topline data of the Phase 1b trial with ATR-12 in Netherton syndrome patients
Financial Results for the Quarter Ended June 30, 2025
- Research and Development (R&D) expenses: R&D expenses for the quarter ended June 30, 2025, were
$1.4 million $1.1 million - General and Administrative (G&A) expenses: G&A expenses for the quarter ended June 30, 2025, were
$1.5 million $1.5 million - Net Loss was
$2.9 million $2.6 million - Cash and cash equivalents: As of June 30, 2025, Azitra had cash and cash equivalents of
$1.0 million
About Azitra, Inc.
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adults with Netherton syndrome. ATR-04, Azitra's additional clinical program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated skin toxicity; a Phase 1/2 clinical trial has been initiated for this program. Azitra has received Fast Track designation from the United States Food and Drug Administration for this program to treat EGFRi associated rash, which impacts approximately 150,000 people in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of (i) our provision of initial safety data and topline results for the phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and (iv) statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may experience delays in the provision of initial safety data and topline results for ATR-12 or, if we do, that such data may not be favorably received, we may fail to present this abstract detailing the Phase 1/2 clinical trial or, if we are able to do so, that the abstract will be favorably received; we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
Condensed Statement of Operations (Unaudited) | ||||||||
Three months Ended June 30, | ||||||||
2025 | 2024 | |||||||
Service revenue – related party | $ | - | $ | 7,500 | ||||
Total revenue | - | 7,500 | ||||||
Operating expenses: | ||||||||
General and administrative | 1,469,513 | 1,549,228 | ||||||
Research and development | 1,401,839 | 1,118,552 | ||||||
Total operating expenses | 2,871,352 | 2,667,780 | ||||||
Loss from operations | (2,871,352) | (2,660,280) | ||||||
Other income (expense): | ||||||||
Interest income | 15,461 | 16,268 | ||||||
Interest expense | (468) | (1,782) | ||||||
Change in fair value of warrants | 54 | 4,272 | ||||||
Other expense | (32,688) | 9,529 | ||||||
Total other income (expense) | (17,641) | 28,287 | ||||||
Net loss before income taxes | (2,888,993) | (2,631,993) | ||||||
Income tax expense | - | - | ||||||
Net loss | $ | (2,888,993) | $ | (2,631,993) | ||||
Net loss attributable to common shareholders | $ | (2,888,993) | (2,631,993) | |||||
Net loss per Share, basic and diluted | $ | (0.18) | $ | (2.74) | ||||
Weighted average common stock outstanding, basic and diluted | 16,279,574 | 960,146 | ||||||
Condensed Balance Sheets (Unaudited) | ||||||||
June 30, | December 31, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 1,045,730 | $ | 4,554,719 | ||||
Other receivables | 78,407 | 101,896 | ||||||
Prepaid expenses and other current assets | 675,553 | 571,675 | ||||||
Total current assets | $ | 1,799,690 | $ | 5,228,290 | ||||
Property and equipment, net | 601,504 | 653,957 | ||||||
Other assets | 1,554,828 | 1,476,555 | ||||||
Total assets | $ | 3,956,022 | $ | 7,358,802 | ||||
Liabilities, and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 635,842 | $ | 490,255 | ||||
Current financing lease liability | 16,854 | 16,066 | ||||||
Current operating lease liability | 286,499 | 255,177 | ||||||
Accrued expenses | 513,166 | 614,359 | ||||||
Total current liabilities | 1,452,361 | 1,375,857 | ||||||
Long-term financing lease liability | 1,479 | 10,105 | ||||||
Long-term operating lease liability | 273,027 | 274,161 | ||||||
Warrant liability | 184 | 381 | ||||||
Total liabilities | 1,727,051 | 1,660,504 | ||||||
Stockholders' equity | ||||||||
Common stock | 1,798 | 763 | ||||||
Additional paid-in capital | 65,750,337 | 63,263,360 | ||||||
Accumulated deficit | (63,523,164) | (57,565,825) | ||||||
Total stockholders' equity | 2,228,971 | 5,698,298 | ||||||
Total liabilities and stockholders' equity | $ | 3,956,022 | $ | 7,358,802 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-announces-q2-2025-results-and-provides-business-updates-302526716.html
SOURCE Azitra, Inc.
FAQ
What were Azitra's (AZTR) key financial results for Q2 2025?
What is the status of Azitra's ATR-12 clinical trial for Netherton syndrome?
How much funding did Azitra (AZTR) secure in Q2 2025?
What is the market potential for Azitra's ATR-04 treatment?
What are Azitra's (AZTR) upcoming milestones for 2025-2026?
